Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: At present, the ideal drug that can prevent, inhibit or stop development of endometriosis, reduce associated pain or infertility and allow conception does not exist. New drugs in development for endometriosis modulate GnRH, estrogen and/or progesterone receptors, or target endometriosis-associated inflammation, angiogenesis, adhesion and/or tissue invasion. Most have been tested in rodents, and have been evaluated in more relevant animal models like nonhuman primates (baboons), but only a few, that is GnRH antagonists, have been tested in human randomized controlled trials. Important safety and efficacy issues remain a concern, as steroid receptors, inflammation, adhesion, angiogenesis and tissue invasion are key factors in physiological events like ovulation, menstruation and embryo implantation. SUMMARY:
|
Authors | Lieven Platteeuw, Thomas D'Hooghe |
Journal | Current opinion in obstetrics & gynecology
(Curr Opin Obstet Gynecol)
Vol. 26
Issue 4
Pg. 243-52
(Aug 2014)
ISSN: 1473-656X [Electronic] England |
PMID | 24978852
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Contraceptives, Oral, Hormonal
- Progestins
- Gonadotropin-Releasing Hormone
|
Topics |
- Animals
- Contraceptives, Oral, Hormonal
(therapeutic use)
- Endometriosis
(complications, drug therapy, pathology)
- Female
- Gonadotropin-Releasing Hormone
(agonists)
- Humans
- Infertility, Female
(drug therapy)
- Mice
- Pain
(drug therapy, etiology, pathology)
- Progestins
(therapeutic use)
|